The ongoing COVID-19 pandemic triggered by SARS-CoV-2 has affected both the economies and health care systems worldwide and has presented significant challenges in the development of vaccines, drugs, and diagnostics.
Since the pandemic, Sino Biological has been intensely monitoring the movement and change of the virus to create “up to date” products.
The company’s antibody products and SARS-CoV-2-related recombinant proteins have been extensively used by scientists from various disciplines and have since produced almost 500 citations to date. These reagents in COVID-19 have been expediting the progress in serological assay development against the SARS-CoV-2 virus.
Sino Biological has also designed the largest bank of recombinant mutant proteins of spike protein, its segments (for example, S1, S2, and RBD), and nucleocapsid. Scientists have actively used the variant proteins to check the phenomena of “antibody evasion” induced by the mutagenesis of main residues in the spike protein.
Featured SARS-CoV-2 spike proteins (Partial)
Table 1. Source: Sino Biological Inc.
Featured SARS-CoV-2 nucleocapsid proteins (Partial)
Table 3. Source: Sino Biological Inc.
Featured SARS-CoV-2 variants (Partial)
Table 5. Source: Sino Biological Inc.
|B.1.351||K417N, E484K, N501Y||40592-V08H85||RBD||His|
|B.1.351||K417N, E484K, N501Y||40592-V31H4||RBD||rFc|
|B.1.1.7||HV69-70 deletion, Y144 deletion, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H||40589-V08B6||S1+S2 ECD||His|
|B.1.351||L18F, D80A, D215G, LAL242-244 deletion, R246I, K417N, E484K, N501Y, D614G, A701V||40589-V08B7||S1+S2 ECD||His|
|B.1.351||D80A, K417N, E484K, N501Y, D614G, A701V||40589-V08B9||S1+S2 ECD||His|
|P.1||L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F||40589-V08B10||S1+S2 ECD||His|
Image Credit: Sino Biological Inc.
Sino Biological has also designed a huge collection of SARS-CoV-2 antibodies for research purposes. Technical data about cross-reactivity, sensitivity, specificity, neutralizing potential, and their validated applications are described below.
BLI assay was used to validate the binding affinity.
Anti-Spike Rabbit MAb (cat#: 40592-R001). Image Credit: Sino Biological Inc.
ELISA assay was performed to verify the cross-reactivity with Spike antigens from various Human Coronaviruses.
The binding between the ACE2 protein and the recombinant spike RBD could be effectively blocked by the anti-RBD neutralizing antibody. This antibody could also suppress the infection of spike pseudovirus to ACE2 overexpressed HEK293T cells.
No cross-reactivity with SARS-CoV, MERS-CoV, HKU1, 229E, NL63, and OC43. Image Credit: Sino Biological Inc.
Anti-Spike RBD Mouse MAb (cat#: 40592-MM57). Image Credit: Sino Biological Inc.
The N and S detection kits use a regular sandwich ELISA, enabling fast quantification of the S and N antigens.
- The assays could be used to measure antigens on the surface of SARS-CoV-2 and/or pseudovirus and also recombinantly expressed antigens
- All antibodies utilized in the kits are monoclonal antibodies that were developed in-house and thus ensure batch-to-batch consistency
SARS-CoV-2 N Detection Kit (KIT40588). Image Credit: Sino Biological Inc.
Sino Biological has recently announced that it has introduced the world’s first coronavirus antigen array under its latest brand called Sinommune™. The new product has been jointly designed by Nanommune Inc., a UCI-based biotech firm that deals in array technology.
The antigen array has been particularly developed for high throughput sero-surveillance analyses of the COVID-19 virus and another type of virus that can cause infections in the upper respiratory tract.
The Sinommune™ has been built by printing recombinant antigens on a membrane coated with nitrocellulose. It can examine serum antibodies against a total of 66 antigens from 23 forms of viruses, such as SARS-CoV-2 and other six coronaviruses, that are responsible for causing respiratory tract infections.
Up to April 30th 2021, there were close to 500 published articles and 120 pre-published publications that have mentioned SARS-CoV-2 reagents or services offered by Sino Biological Inc.
- Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. SCIENCE CHINA Life Sciences.2020
- Bo Diao, Zeqing Feng. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv preprint
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological’s products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers’ one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.